Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy


Summary

Background and objectives The discovery of different podocyte autoantibodies in membranous nephropathy (MN) raises questions about their pathogenetic and clinical meaning. This study sought to define antibody isotypes and correlations; to compare levels in MN, other glomerulonephritides, and controls; and to determine their association with clinical outcomes.

Design, setting, participants, & measurements Serum IgG1, IgG2, and IgG4 against aldose reductase (AR), SOD2, and α-enolase (αENO) were measured at diagnosis in 186 consecutive MN patients, in 96 proteinuric controls (36 with FSGS, and 60 with IgA nephropathy), and in 92 healthy people recruited in four Italian nephrology units. Anti-phospholipase A2 receptor (PLA2r) and anti-neutral endopeptidase (NEP) IgG4 were titrated in the same specimens. Association with 1-year follow-up clinical parameters was studied in 120 patients.

Results IgG4 was the most common isotype for all antibodies; IgG1 and IgG3 were nearly negligible. IgG4 levels were higher in MN than in healthy and pathologic controls (P<0.005). Anti-NEP IgG4 did not differ from normal controls (P=0.12). Anti-PLA2r IgG4 was detected in 60% of patients and correlated with anti-AR, anti-SOD2, and anti-αENO IgG4 (P<0.001). In MN patients negative for the whole antibody panel (20%), 1-year proteinuria was lower compared with patients with at least one antibody positivity (P<0.05).

Conclusions Our data suggest that IgG4 is the prevalent isotype for antibodies against cytoplasmic antigens of podocytes (AR, SOD2, αENO). Their levels were higher than in other proteinuric glomerulonephritides and in normal controls and were correlated with anti-PLA2r. Only baseline negativity for all known antibodies predicted lower 1-year proteinuria.

Introduction

Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults (1). Glomerular damage is produced by the deposition of subepithelial immune deposits that consist mainly of IgG4 and C5b-9 (2,3). The definition of causative autoantibodies and their renal targets is essential to understand the mechanisms of disease development and progression.

Recent findings indicate that more than one podocyte protein may act as an autoantigen in human MN (4). Identified antigens are membrane proteins, such as phospholipase A2 receptor (PLA2r) (5) and neutral endopeptidase (NEP) (6), and components of the cytoplasm, such as aldose reductase (AR), SOD2, and α-enolase (αENO) (7,8). Circulating levels of the corresponding autoantibodies might be used as biomarker of disease activity.

With the exception of a report of maternal anti-NEP antibodies in antenatal MN (6,9), data on autoantibodies are limited to anti-PLA2r antibodies. Anti-PLA2r IgG4 have been described as the largely predominant circulating and glomerular isotype in MN patients (5). They seem specific (89%) for idiopathic MN (10–12) and can be utilized as support to exclude secondary MN (10). However, several MN patients are anti-PLA2r negative (30%–50% according to case series) whereas in others, anti-PLA2r positivity persists after response to therapy (11,13). Data on anti-PLA2r do not exclude the presence of other circulating autoantibodies such as anti-cytoplasmic antigens of podocytes, whose serum levels might be detected and might be useful in clinical practice.

To test this hypothesis, we measured the levels of antibodies against both membrane and cytoplasmic autoantigens in patients with and without MN. Our objectives were as follows: (1) to define the prevalent isotype for each anti-cytoplasmic antibody and the spectrum of MN patients in respect to positivity or negativity for the whole panel of currently known antibodies; (2) to compare their levels in participants with MN versus patients suffering from other proteinuric glomerular nephropathies.
diseases or normal controls; and (3) to ascertain whether a relationship exists between the type and level of these antibodies and clinical outcome in individuals with MN.

Materials and Methods
Assembled Cohort
We conducted a retrospective study at four Italian nephrology centers in Parma, Modena, Milano, and Bari. We recruited patients with newly diagnosed MN or other proteinuric nephropathies and normal controls over 2 years (2008–2010). Ethical approval to test antibody levels was obtained from the Giannina Gaslini Institute Ethics Committee. The study was registered in the EudraCT registry (EudraCT 2011–003942–41).

MN Patients. We recruited 186 consecutive patients with idiopathic MN, who gave informed consent to have the serum antibody levels titrated at the time of renal biopsy, before any therapy was started (Table 1). At the time enrollment was closed, 120 patients had completed a follow-up of 12 months or longer, during which they had received different therapy schemes, mainly the Ponticelli schedule (Supplemental Table 1). Criteria for enrollment were as follows: histologically proven MN; negative tests for serum autoantibodies (antinuclear antibody, ANCA), cryoglobulins, and viral markers (hepatitis B surface antigen, HIV); absence of any clinical suspicion of secondary MN; or absence of any previous immunosuppressive treatment.

Proteinuric Controls. Ninety-two patients with different nephropathies were recruited at the same institutions: 32 patients with FSGS and 60 with IgA nephropathy (IgAN). Diagnosis was always based on histologic criteria. To provide similar clinical conditions to MN patients, FSGS specimens were all collected during a relapse of nephrotic proteinuria. IgAN patients had to present with proteinuria >0.3 g/d and to be free of any immunosuppressive therapy at the time of serum collection (Table 1).

Normal Controls. Serum was obtained from 96 normal controls recruited at the same institutions. They consisted of normal blood donors who had at least one normal urinalysis and serum tests in the prior 6 months (Table 1).

Assays for Autoantibodies
Anti-AR, Anti-SOD2, and Anti-ENO. Circulating IgG1, IgG2, and IgG4 levels against AR, SOD2, and ENO in sera were determined with dot blot utilizing recombinant proteins fixed to nitrocellulose as antigens, as previously described (7,8). Details of the method and examples of variable positivity are given in the Supplemental Methods and Supplemental Figure 1. Antibody positivity was defined as a serum level exceeding the 95th percentile of levels titrated in normal controls.

Anti-PLA2r. Circulating anti-PLA2r IgG4 antibodies were titrated by Western blot against podocyte protein extracts (kindly offered by Dr. Saleem, University of Bristol, Bristol, UK) previously separated in gradient monodimensional electrophoresis (14) and then incubated with serum. The technique is described in detail in the Supplemental Methods. Anti-PLA2r autoantibodies were also evaluated in a random subsample of MN patients (n=73) by indirect immunofluorescence with a commercially available test, according to the manufacturer’s instructions (Euroimmun, Lubeck, Germany) (15). Details of the method are given in the Supplemental Methods and Supplemental Table 2.

Anti-NEP. Circulating IgG4 antibodies against NEP were assessed by dot blot utilizing recombinant NEP as fixed antigen. The assay is based on the same technique described for anti-AR, anti-SOD2, and anti-ENO, and is reported in the Supplemental Methods.

Statistical Analyses
Data were described using frequencies, means, and SDs, as appropriate. Natural log transformation was performed on non-normally distributed variables before using linear models. Due to the presence of several “zeros,” baseline correlations were performed using the Spearman rank correlation method for non-normally distributed variables; natural log transformation was performed after adding 0.01 to each variable value. The Mann–Whitney U test was used to compare non-normally distributed variables. Separate univariable logistic models were used with presence of MN versus other nephropathies or controls as binary outcomes to estimate the area under the receiver operating characteristic (ROC) curves. Logistic regression models of 1-year proteinuria were built on log-transformed antibody values adjusting for baseline levels of log2-proteinuria. Two models were built with the dichotomous outcome defined as complete or partial remission (proteinuria <0.3 or <3.5 g/d). Linear regression models

| Table 1. Clinical characteristics of patients and controls enrolled in this study |
|------------------------------------|------------------|------------------|------------------|------------------|
| MN (n=186) | FSGS (n=32) | IgAN (n=60) | Normal (n=96) |
| Male sex | 121 (65) | 19 (59) | 38 (63) | 56 (58) |
| Age (yr) | 59 ± 16 | 18 ± 3 | 40 ± 4 | 49 ± 10 |
| Race | | | | |
| Caucasian | 184 (99) | 32 (100) | 56 (93) | 96 (100) |
| Other | 2 (1) | 4 (7) | | |
| Diabetes | 24 (13) | 0 (0) | 4 (7) | 0 (0) |
| Serum creatinine (mg/dl) | 1.1 (0.3–6) | 0.6 (0.3–1) | 0.9 (0.5–1.3) | 0.9 (0.6–1.2) |
| Proteinuria (g/d) | 5.8 (0.3–28) | 6.0 (3.6–12.4) | 1.55 (0.9–3.4) | 0 |

Data are presented as n (%) or mean ± SD, or as median (range) for those with non-normal distribution. Clinical data were collected at the time of serum sample collection. Proteinuria in normal controls was tested by urine dipstick. MN, membranous nephropathy; IgAN, IgA nephropathy.
of log2-proteinuria adjusted for baseline proteinuria were also built on each antibody level. Similarly, linear models were used to study the associations between levels of antibodies and serum albumin. Models with only one antibody at a time were built for reasons of colinearity. Model assumptions and goodness of fit were verified looking at formal tests and graphical tests based on residuals. All statistical analyses were performed with STATA/MP 12.1 software (StataCorp, College Station, TX).

Results

Patients with MN were prevalently male (65%) and had a mean age of 59±16 years. All were proteinuric at the time of enrollment and had variable creatinine levels (Table 1). Patients with FSGS (59% male) had proteinuria >3.5 g/d, had normal renal function in all cases, and were younger (age 18±3 years). IgAN patients (63% male; 40±4 years) had proteinuria 0.9–3.4 g/d and normal renal function. Normal controls were prevalently male (58%) with a mean age of 49±10 years (Table 1).

Antibody Levels in MN and in Other Glomerulonephritides

Anti-AR, Anti-SOD2, and Anti-αENO Antibody Isotypes/Serum Levels. Circulating anti-AR, anti-SOD2, and anti-αENO isotypes (IgG1, IgG3, and IgG4) and levels were determined by dot blot in the serum of 186 MN patients at diagnosis (Figure 1). Isotype characterization of each specificity indicated that IgG4 is the predominant IgG subclass. Anti-AR and anti-SOD2 IgG4 and IgG3 were, in fact, only sporadically positive (~3%). Anti-αENO IgG1–3 were instead increased in a small but significant proportion of MN patients (13% IgG1 and 7% IgG3) (Supplemental Figure 2). In patients with other nephropathies, serum levels of each IgG4 antibody were found to be lower than in normal controls; one IgAN patient presented an isolated anti-αENO positivity (Figure 1). The percentage of MN patients with IgG4 positive levels was highly significant (AR, 34%; SOD, 26%; αENO, 43%; P<0.001 for all) (Supplemental Figure 3). Comparison of levels confirmed significantly higher circulating levels of anti-AR, anti-SOD2, and anti-αENO IgG4 in MN patients compared with either normal participants or other nephropathies (Table 2). The area under the ROC curves for each antibody was significantly greater in MN patients compared with patients with other nephropathies or normal participants, although to a lesser extent (Figure 2).

Anti-PLA2r and Anti-NEP Antibodies. Anti-PLA2r IgG4 was detected by Western blot in 111 MN patients (Figure 3), giving a final estimate of 60% of patients being positive (Supplemental Figure 3), confirming previous studies (5,10). In a random portion of MN sera (73 patients), anti-PLA2r total IgG as determined by indirect immunofluorescence (12,15) confirmed results of Western blot titration (Spearman analysis, p=0.91; P<0.001) (Supplemental Table 2). Anti-NEP IgG4 serum levels were determined with dot blot analysis. The results shown in Figure 3 indicate a minor percentage (17%) of MN patients with anti-NEP positivity. NEP serum levels were not higher in MN patients than in normal serum (P=0.12) (Table 2).

Multiple Positivity. Many MN patients presented concomitant high serum levels of more than one antibody. Anti-PLA2r serum levels correlated with all the other antibodies and anti-AR correlated with anti-SOD2 (Table 3) (P<0.001 in all cases). Simultaneous multiple positivity or negativity for the antibody panel was tested in the whole cohort of patients: 19 sera (10%) were completely positive and 37 (20%) were negative. Most patients (70%) presented intermediate positivity for one, two, or three antibodies
Of the 75 anti-PLA2r-negative patients, 38 (51%) were positive for at least one other antibody (Supplemental Figure 4).

Clinical Correlations
There was no relationship between antibody levels and proteinuria, renal function, and histologic stage at baseline. No histologic or clinical characteristics distinguished anti-PLA2r-positive and anti-PLA2r-negative patients. Antibody levels failed to predict the probability to reach complete (0.3 g/d) or partial (3.5 g/d) remission after 1 year. When proteinuria was modeled as a continuous variable, only anti-AR IgG4 levels predicted 1-year proteinuria. Similarly, only anti-aENO IgG4 significantly predicted serum albumin levels at 12 months (Supplemental Table 3). Finally, 27 MN patients who were negative for all antibodies completed the 12-month follow-up (Table 4). Of the 75 anti-PLA2r-negative patients, 38 (51%) were positive for at least one other antibody (Supplemental Figure 4).

Discussion
The recent discovery that podocyte proteins are targets of circulating antibodies in human MN represented a breakthrough in the research on MN pathogenetic mechanisms (5,7,8). However, the implication of more than one antigen in the formation of subepithelial immune deposits raises questions about the clinical significance of each autoantibody. Thus far, four podocyte antigens have been studied in primary MN: PLA2r was the first discovered (and deeply investigated) (5,11,13), and AR, SOD2, and aENO were subsequently identified (7,8). Our study was planned to bridge the gap of knowledge on antibodies against neo-expressed cytoplasm antigens (i.e., anti-AR, anti-SOD2, and anti-aENO). In fact, there is little information in the literature about their serum levels and their correlation with anti-PLA2r. Moreover, the evaluation of a potential association of serum antibody levels (including anti-PLA2r) with clinical outcomes requires studies in large cohorts of patients. Our strategy was therefore based on the concomitant determinations of serum levels of anti-cytoplasmic proteins (Table 4).

### Table 2. Levels of circulating antibodies in MN patients, controls, and other nephropathies

<table>
<thead>
<tr>
<th></th>
<th>MN</th>
<th>Controls</th>
<th>FSGS</th>
<th>IgAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-AR</td>
<td>37.90 (7.12–121.90)</td>
<td>29.67 (9.39–47.36)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.38 (3.43–9.15)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>9.39 (4.41–14.46)&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anti-SOD2</td>
<td>84.34 (35.51–223.60)</td>
<td>33.92 (4.11–62.23)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6.89 (4.16–9.69)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>9.09 (3.93–12.99)&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anti-aENO</td>
<td>110.40 (27.84–237.70)</td>
<td>47.80 (31.09–67.38)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5.40 (3.29–9.43)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>9.31 (5.06–18.19)&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anti-NEP</td>
<td>53.52 (3.52–211.20)</td>
<td>32.42 (14.95–54.73)</td>
<td>4.08 (2.08–6.92)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7.05 (3.67–11.39)&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anti-PLA2r</td>
<td>40.26 (13.12–96.76)</td>
<td>Undetectable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are expressed as chemiluminescence OD arbitrary units and presented as median (interquartile range). Only data of 111 positive patients were reported for anti-PLA2r. MN, membranous nephropathy; IgAN, IgA nephropathy; AR, aldose reductase; aENO, a-enolase; NEP, neutral endopeptidase; PLA2r, phospholipase A2 receptor.

<sup>a</sup>A highly statistically significant difference with MN level (two tailed Mann–Whitney U test). P=0.004.

<sup>b</sup>A highly statistically significant difference with MN level (two tailed Mann–Whitney U test). P<0.001.

Figure 2. | ROC curves. The area under the ROC curves for each antibody was significantly greater in MN patients compared with (A) patients with other nephropathies or (B) normal participants, although to a lesser extent. ROC, receiver operating characteristic; MN, membranous nephropathy.

Discussion
The recent discovery that podocyte proteins are targets of circulating antibodies in human MN represented a breakthrough in the research on MN pathogenetic mechanisms (5,7,8). However, the implication of more than one antigen in the formation of subepithelial immune deposits raises questions about the clinical significance of each autoantibody. Thus far, four podocyte antigens have been studied in primary MN: PLA2r was the first discovered (and deeply investigated) (5,11,13), and AR, SOD2, and aENO were subsequently identified (7,8). Our study was planned to bridge the gap of knowledge on antibodies against neo-expressed cytoplasm antigens (i.e., anti-AR, anti-SOD2, and anti-aENO). In fact, there is little information in the literature about their serum levels and their correlation with anti-PLA2r. Moreover, the evaluation of a potential association of serum antibody levels (including anti-PLA2r) with clinical outcomes requires studies in large cohorts of patients. Our strategy was therefore based on the concomitant determinations of serum levels of anti-cytoplasmic proteins (Table 4). Of the 75 anti-PLA2r-negative patients, 38 (51%) were positive for at least one other antibody (Supplemental Figure 4).
antigen antibodies and comparisons with anti-PLA2r in the same patient population.

Our results showed that high levels of circulating anti-bodies against cytoplasm podocyte proteins (AR, SOD2, and αENO) are present in a significant number of MN patients. The predominant isotype was IgG4 in all cases, although the levels of IgG1 were not completely negligible. On the other hand, circulating levels of IgG4 anti-PLA2r and other IgG4 antibodies correlated at the time of diagnosis, suggesting a common formation mechanism. Anti-NEP IgG4 seemed to play a secondary role.

Some limitations of this study must be acknowledged. Follow-up sera were not available, and thus we could not perform a lengthwise evaluation of autoantibody levels and laboratory parameters. Further studies, now in progress, will bridge this knowledge gap. Moreover, circulating serum IgG subclass measurement was not available. A correlation of single specificities with the respective total IgG isotype level could not be verified. Truthfully, none of the previous seminal studies on anti-podocyte antibodies in MN reported such data (5,10–12); when planning brand new studies on MN, researchers will need to consider this recurring limitation. Lastly, a group of secondary MN was not available for comparison; a definitive evaluation of the specificity of anti-cytoplasmic podocyte antigen antibodies is not possible with the data analyzed in our study.

Despite the considerations above, our study is the first to attempt correlating serum levels of different antibody specificities in the same patient population. Owing to the large number of patients recruited and the fact that they were all enrolled at the time of disease diagnosis (patients recruited in other studies had a variable disease duration from 4 to 144 months), our results add significant knowledge to the studies on MN that evaluated only anti-PLA2r antibodies. Moreover, our study adds relevant data on the definition of anti-PLA2r outliers (i.e., patients who are anti-PLA2r negative despite an active disease). Indeed, we found that only 37 patients (20%) were negative for all antibodies, a small proportion of those negative for anti-PLA2r alone (40%). Interestingly, only negativity for the complete panel is associated with lower proteinuria after 1 year. Although no single antibody level has significant independent prognostic ability, negativity to all antibodies does. Our data cannot help understand whether this subgroup represents a different pathologic entity or a MN cluster with immunologic inactive disease that evolves toward spontaneous remission. However, recent advice to dose

<table>
<thead>
<tr>
<th>Table 3. Spearman’s rank correlation coefficient between serum antibodies titers at the time of diagnosis in MN patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>AR</td>
</tr>
<tr>
<td>SOD2</td>
</tr>
<tr>
<td>αENO</td>
</tr>
</tbody>
</table>

Data are expressed as ρ for each correlation. MN, membranous nephropathy; αENO, α-enolase; PLA2r, phospholipase A2 receptor; AR, aldose reductase.

*Indicates an highly statistically significant correlation (P<0.001).
anti-PLA2r to define MN activity (16,17) and thus to drive the therapeutic approach is challenged by the results of this study. Further data from different MN cohorts are needed to confirm the advantage of the use of the complete panel of antibodies to individualize the therapeutic approach.

A few considerations on MN pathogenesis emerge from this study. The first consideration is the temporal sequence of autoantibody production. Although this should be proven in an experimental model, we propose that the temporal appearance of detectable antibodies may follow a common mechanism. Although we cannot evaluate the timing of antibody production in the preclinical phase, it is possible that podocyte overexpression and de-localization of SOD2 and AR may represent an antioxidant response preceding the humoral immune response. In Heymann nephritis (18,19), podocyte-produced oxygen radicals in the presence of CsA-9 mediate glomerular damage (20,21). In this light, anti-SOD2 and anti-AR antibodies should follow a first autoimmune phase. However, autoantibody formation in MN may require a more complex and disease-specific mechanism than a generic podocyte injury, as confirmed by the minimal antibody serum levels in FSGS, the prototype of podocytopathy. In fact, we showed a lower circulating level of anti-AR, anti-SOD2, and anti-α-ENO in IgAN and FSGS compared with normal controls (as confirmed by the better performance of ROC curves comparing MN with other nephropathies). These data suggest an effect of proteinuria and/or minor total Ig serum levels in lowering anti-cytoplasmic podocyte antigen antibodies and support the concept that the production of such antibodies is a disease-specific mechanism in MN.

A second consideration concerns the role of α-ENO. Circulating anti-α-ENO IgG has been reported in various autoimmune diseases (22–24). When characterized, the prevalent isotype was of the IgG1 and IgG2 subclasses also in previous reports on MN patients (25), whereas anti-α-ENO IgG4 seems to be more specific for MN (8). Because the shift from IgG1 to IgG4 formation is a slow process that requires a complex machinery involving T helper-2, B cell activation, and IL-3/13/10 (26), the prevalence of IgG4 in the serum and within the glomeruli of MN patients suggests that the isotype switch may be a specific mechanism of the disease rather than a marker of inflammation. Because our data do not allow any conclusion on the role of anti-α-ENO IgG4 and IgG3 in MN, we cannot exclude that they are also involved in immune-deposit formation and podocyte damage.

In conclusion, our study demonstrates that all recently described serum anti-podocyte antibodies are increased in MN at diagnosis. Although no strong association with clinical outcome was found for any single autoantibody, follow-up proteinuria is lower in patients who are negative for all antibodies. A panel including all antibodies is therefore the most promising biomarker to be tested and utilized in prospective studies.

Coexistence of autoantibodies suggests a complex pathogenetic pathway that involves different podocyte targets. New experimental models are needed to elucidate the appearance time and the role of each anti-podocyte antibody in MN development and progression.

Acknowledgments
This study was investigator initiated and driven. The authors thank Dr. Saleem (University of Bristol, Bristol, UK) for supplying human conditionally immortalized podocyte cell lines, as well as Professor Gianni Cappelli for helpful discussion.

Istituto Giannina Gaslini provided financial and logistic support for this trial. This work was also supported by the Italian Ministry of Health “Ricerca Corrente,” the Renal Child Foundation, Fondazione Mara Wilma e Bianca Querci (“Ruolo dello stress reticolare nella progressione del danno renale e tumorale” project), and Fondazione La Nuova Speranza (“Progetto integrato per la definizione dei meccanismi implicati nella glomerulosclerosi focale”).

Part of these results were presented in abstract form at the Eighth International Congress on Autoimmunity, May 8–13, 2012, Granada, Spain.

Disclosures
None.

References

---

Table 4. Subgroup analysis of MN patients by number of baseline antibody positivity

<table>
<thead>
<tr>
<th>Number of Positive Autoantibodies</th>
<th>4</th>
<th>3</th>
<th>2</th>
<th>1</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>In 186 patients</td>
<td>19  (10)</td>
<td>25  (13)</td>
<td>55  (30)</td>
<td>50  (27)</td>
<td>37  (20)</td>
</tr>
<tr>
<td>In 120 patients</td>
<td>10  (8)</td>
<td>18  (15)</td>
<td>36  (30)</td>
<td>29  (24)</td>
<td>27  (23)</td>
</tr>
<tr>
<td>Proteinuria T0 (g/d)</td>
<td>3.91 (2.8–6.5)</td>
<td>4.35 (2.8–8.6)</td>
<td>6.00 (4.3–9.2)</td>
<td>4.74 (2.7–7.3)</td>
<td>5.90 (3.6–7.8)</td>
</tr>
<tr>
<td>Proteinuria T12 (g/d)</td>
<td>1.24 (0.2–2.2)</td>
<td>2.85 (0.5–6.8)</td>
<td>1.38 (0.1–4.4)</td>
<td>1.10 (0.4–3.2)</td>
<td>0.33 (0.1–1.8)</td>
</tr>
<tr>
<td>Complete remission</td>
<td>3    (30)</td>
<td>4    (22)</td>
<td>12   (33)</td>
<td>6    (21)</td>
<td>13   (48)</td>
</tr>
</tbody>
</table>

Data are presented as n (%) or median (interquartile range). Autoantibodies considered are against PLA2r, AR, SOD2, and α-ENO. Clinical data reported are referred to the group of patients who completed the 1-year clinical follow-up (120 patients). Complete remission is defined as proteinuria <0.3 g/d. MN, membranous nephropathy; T0, proteinuria at diagnosis; T12, proteinuria after 1 year of follow-up; PLA2r, phospholipase A2 receptor; AR, aldose reductase; α-ENO, α-enolase.

Received: March 1, 2012 Accepted: June 5, 2012
C.M. and M.B. contributed equally to this work.

Published online ahead of print. Publication date available at www.cjasn.org.

This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.02170312/-/DCSupplemental.